CN103816281B - A kind of Chinese medicine composition of prevention and treatment anemopyretic cold - Google Patents
A kind of Chinese medicine composition of prevention and treatment anemopyretic cold Download PDFInfo
- Publication number
- CN103816281B CN103816281B CN201410082674.0A CN201410082674A CN103816281B CN 103816281 B CN103816281 B CN 103816281B CN 201410082674 A CN201410082674 A CN 201410082674A CN 103816281 B CN103816281 B CN 103816281B
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- anemopyretic cold
- medicine
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 56
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 230000002265 prevention Effects 0.000 title claims abstract description 10
- 241000628997 Flos Species 0.000 claims abstract description 28
- 239000000341 volatile oil Substances 0.000 claims abstract description 21
- 239000010231 banlangen Substances 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 239000002775 capsule Substances 0.000 claims description 35
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 241000245240 Lonicera Species 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 206010011224 Cough Diseases 0.000 abstract description 22
- 208000002193 Pain Diseases 0.000 abstract description 15
- 230000036407 pain Effects 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 10
- 238000012360 testing method Methods 0.000 abstract description 5
- 206010037660 Pyrexia Diseases 0.000 abstract description 2
- 230000008092 positive effect Effects 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 229940079593 drug Drugs 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 231100000614 poison Toxicity 0.000 description 12
- 239000003440 toxic substance Substances 0.000 description 12
- 230000037396 body weight Effects 0.000 description 11
- 230000008961 swelling Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 241000191967 Staphylococcus aureus Species 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000000214 mouth Anatomy 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 239000002510 pyrogen Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 210000000115 thoracic cavity Anatomy 0.000 description 6
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 230000036760 body temperature Effects 0.000 description 5
- 229960004756 ethanol Drugs 0.000 description 5
- 210000003026 hypopharynx Anatomy 0.000 description 5
- 208000033065 inborn errors of immunity Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 210000004243 sweat Anatomy 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010068319 Oropharyngeal pain Diseases 0.000 description 4
- 201000007100 Pharyngitis Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- -1 alpha-cyclodextrin Chemical class 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 239000012567 medical material Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000021251 pulses Nutrition 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 206010014025 Ear swelling Diseases 0.000 description 3
- 208000002151 Pleural effusion Diseases 0.000 description 3
- 206010039101 Rhinorrhoea Diseases 0.000 description 3
- 208000033809 Suppuration Diseases 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000001166 anti-perspirative effect Effects 0.000 description 3
- 239000003213 antiperspirant Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000007667 floating Methods 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 231100000668 minimum lethal dose Toxicity 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 208000010753 nasal discharge Diseases 0.000 description 3
- 230000003448 neutrophilic effect Effects 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000005057 refrigeration Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 201000000297 Erysipelas Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 239000004368 Modified starch Substances 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- 206010028748 Nasal obstruction Diseases 0.000 description 2
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229960002800 prednisolone acetate Drugs 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 244000296912 Ageratum conyzoides Species 0.000 description 1
- 235000004405 Ageratum conyzoides Nutrition 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 235000016535 Capraria biflora Nutrition 0.000 description 1
- 241000208828 Caprifoliaceae Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 241000334160 Isatis Species 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 244000167230 Lonicera japonica Species 0.000 description 1
- 235000017617 Lonicera japonica Nutrition 0.000 description 1
- 241001570521 Lonicera periclymenum Species 0.000 description 1
- 241000219071 Malvaceae Species 0.000 description 1
- 241001276052 Merremia umbellata subsp. orientalis Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 244000274050 Platycodon grandiflorum Species 0.000 description 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000257673 Strobilanthes cusia Species 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229960002588 cefradine Drugs 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000011169 microbiological contamination Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000009874 shenqi Substances 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- ZPCCSZFPOXBNDL-RSMXASMKSA-N spiramycin II Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]([C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)OC(C)=O)[C@H]1CC[C@H](N(C)C)[C@H](C)O1 ZPCCSZFPOXBNDL-RSMXASMKSA-N 0.000 description 1
- 229950006796 spiramycin ii Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The Chinese medicine composition of a kind of prevention and treatment anemopyretic cold, the raw material preparing described compositions mainly includes Radix Helicteris and Radix Picriae felterrae, it is also possible to increase other Chinese medicine according to the state of an illness, and such as Radix Isatidis and Flos Lonicerae etc., Flos Lonicerae used refers to the volatile oil extracted with Flos Lonicerae.Test outside a large amount of clinical precursor, zoopery, and clinical trial certificate, the effect such as fever that the medicine of the present invention causes for anemopyretic cold, cough, pain has positive effect.
Description
Technical field:
The invention belongs to the field of Chinese medicines, relate to a kind of prevention and the Chinese medicine composition for the treatment of anemopyretic cold.
Background technology:
Flu is the common exogenous diseases that being invaded by exogenous pathogen causes.During due to four, six gas are different, and human quality's difference, therefore clinic has wind and cold, wind heat and heat-damp in summer accompanied symptoms.Such as anemopyretic cold, owing to wind heat violates table, the heat stagnation flesh natural fibre line of meat, defending table discord, therefore see fever of the body, micro evil wind is trembled with fear, sweating is not smooth；Wind-heat troubling, then distending pain in the head；The heresy of wind heat is stifling cleans the street, therefore laryngopharynx swelling and pain, parched throat, thirst with desire to drink, turbid nasal discharge；Wind-heat invading the lung, impairment of purifying function of the lung, then cough, expectoration be viscous or Huang, tongue tip side of red, thin white fur of tongue or micro-Huang, floating and rapid pulse are that wind heat is invaded in levying that lung is defended.This disease is attacked caused by human body mainly due to wind-heat evil toxin, therefore its treatment is when with dispelling wind to relieve the exterior syndrome, heat-clearing and toxic substances removing for the rule for the treatment of.
Anemopyretic cold is the common high morbidity in the subtropical zones such as Guangxi.Although having the proved recipe much with better clinical effectiveness, such as application number: CN200810073696.5) prescription adopts " Folium Eucalypti Robustae and Flos Ilicis Asprellae "；Patent " a kind of Chinese medicinal tablet or capsule and preparation method thereof treating anemopyretic cold, upper respiratory tract infection, application number: CN201110456838.8 " prescription adopts " Flos Ilicis Asprellae, Herba lygodii, Radix achyranthis asperae (Herba Achyranthis Asperae) and Merremia umbellata subsp. orientalis "；Patent " the Chinese medicine preparation application number of a kind of Rhizoma Et Radix Baphicacanthis Cusiae: CN201310191571.3 " prescription adopts " Rhizoma Et Radix Baphicacanthis Cusiae " etc..But have no and adopt Guangxi conventional crude drugs Radix Helicteris and Radix Picriae felterrae to carry out prescription the medicine adopting modern technology of preparing to be prepared from.
Summary of the invention:
It is an object of the invention to provide a kind of prevention and the Chinese medicine for the treatment of anemopyretic cold, there is dispelling wind to relieve the exterior syndrome, heat-clearing and toxic substances removing, dredging microcirculation, and cure rate is high.
The technical scheme is that such:
A kind of Chinese medicine composition treating anemopyretic cold, the raw material preparing described compositions includes Radix Helicteris and Radix Picriae felterrae, and the amount ratio of the two is: Radix Helicteris 6～8 parts, and Radix Picriae felterrae 5～7 parts, described part is weight portion.
With the drug matching of conventional treatment flu, in one optimization formula of the present invention, can also including Radix Isatidis and/or Flos Lonicerae in above-mentioned composition, Flos Lonicerae used refers to the medicinal residues after the volatile oil with Flos Lonicerae extraction and extraction；
The preparation method of described Flos Lonicerae volatile oil and form can adopt this area convenient technical process, after such as Flos Lonicerae being extracted volatile oil, make inclusion agent according to a conventional method, are subsequently used for the preparation of this pharmaceutical preparation.
The parts by weight proportioning of each raw material is: Radix Helicteris 6～8 parts, Radix Picriae felterrae 5～7 parts, 5～7 parts and 5～7 portions Flos Loniceraes of Radix Isatidis.
Can also adding Radix Platycodonis and/or Radix Glycyrrhizae in above-mentioned formula, consumption is Radix Platycodonis 1.6～2.4 parts, 1.6～2.4 parts of Radix Glycyrrhizae.
A kind of preferred parts by weight proportioning is: Radix Helicteris 7 parts, Radix Picriae felterrae 7 parts, Flos Lonicerae 6 parts, Radix Isatidis 6 parts, Radix Platycodonis 2 parts and 2 parts of Radix Glycyrrhizae.
The monarch drug playing main work in we is Radix Helicteris and Radix Picriae felterrae；Ministerial drug Flos Lonicerae, Radix Isatidis；Adjuvant drug Radix Platycodonis, Radix Glycyrrhizae；
Radix Helicteris, the micro-hardship of acrid in the mouth, cool in nature, there are relieving the exterior syndrome with drugs of pungent in flavor and cool in nature, heat-clearing and toxic substances removing, reducing swelling and alleviating pain function.
Radix Picriae felterrae, bitter in the mouth, cold in nature, there are heat-clearing and toxic substances removing, reducing swelling and alleviating pain function.
Although Radix Helicteris and this two tastes medicine of Radix Picriae felterrae are all individually found there is the effect to flu, but have no the effect of two medicine compatibilities in prior art.
The inventors discovered that the compatibility of two medicines has synergism for heat-clearing and toxic substances removing, reducing swelling and alleviating pain.
Flos Lonicerae, bitter in the mouth, cold in nature, heat-clearing and toxic substances removing, and have the light merit declaring evacuation, for anemopyretic cold common medicine；Radix Isatidis, bitter in the mouth, cold in nature, heat-clearing and toxic substances removing, for affection due to external wind and heat, heating, laryngopharynx swelling and pain etc..Upper two medicines strengthen monarch drug dispelling wind to relieve the exterior syndrome, heat-clearing toxin-expelling functions, for ministerial drug in side.
Radix Platycodonis, bitter in the mouth is pungent, and property is put down, and opens lung qi dispersing gas, expelling phlegm for arresting cough；Radix Glycyrrhizae nourishing the lung to arrest cough, relieving spasm to stop pain, upper two medicines share lung qi dispersing eliminating phlegm and stopping cough, for adjuvant drug in side.
The raw material of Chinese medicine medicine pharmacological property of the above Chinese medicine composition:
1, the dry root of Radix Helicteris system Sterculiaceae plant Radix Helicteris HelicteresangustifoliaL. or Herb.Property bitter, cold.Function heat-clearing and toxic substances removing, is used for high heat of catching a cold, tonsillitis, pharyngolaryngitis, parotitis, skin eczema.
2, the dry herb of Radix Picriae felterrae system goatweed Picriafel-terraeLour..Property bitter, cold.Function heat-clearing and toxic substances removing, reducing swelling and alleviating pain.For cold anemopyretic, laryngopharynx swelling and pain, mumps, gastric heat is suffered from abdominal pain, dysentery, furuncle and phyma, venom.
3, the flower that the dry flower of Flos Lonicerae system caprifoliaceae plant Radix Ophiopogonis LonicerajaponicaThunb. or band are just opened.Property sweet, cold.Function heat-clearing and toxic substances removing, wind-heat dissipating.For carbuncle furuncle, sore throat, erysipelas, toxic-heat and blood stasis, anemopyretic cold, pestilence is generated heat.
4, the dry root of Baphicacanthus cusia root system cruciferae isatis IsatisindigoticaFort..Property bitter, cold.Function heat-clearing and toxic substances removing, removing heat from blood sore-throat relieving.For maculae caused by violent heat pathogen, crimson tongue is dark violet, mumps, sore throat, scarlet fever, major part pestilence, erysipelas, carbuncle.
5, the dry root of Radix Platycodonis system Campanulaceae Radix Platycodonis Platycodongrandiflorum (Jacq.) A.DC..Property bitter, pungent, flat.Function lung qi dispersing, sore-throat relieving, eliminate the phlegm, evacuation of pus.For cough with copious phlegm, uncomfortable in chest not smooth, pharyngalgia, hoarseness, lung abscess vomiting pus, skin infection difficulty in discharging of pus.
6, the dry root and rhizome of Radix Glycyrrhizae system glycyrrhizic legume GlycyrrhizauralensisFisch., Glycyrrhiza inflata Bat. GlycyrrhizainflataBat. or Glycyrrhiza glabra L. GlycyrrhizaglabraL..Property sweet, flat.Function invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.For weakness of the spleen and stomach, fatigue and weakness, shortness of breath and palpitation, cough with copious phlegm, gastral cavity abdomen, extremity contraction urgency pain, carbuncle sore tumefacting virus, cushion toxicity, strong.
The above raw material of Chinese medicine can mix with pharmaceutically acceptable adjuvant, makes various oral formulations, such as powder, capsule, tablet, electuary etc..
In one embodiment of the present invention, preparation method is:
1) Flos Lonicerae volatile oil inclusion complex is prepared
After extracting Flos Lonicerae volatile oil by the method for traditional extraction volatile oil, adding inclusion material and prepare into inclusion complex, the remaining Flos Lonicerae medicinal residues of institute give over to lower step and use.
2) being cut off respectively by other medical material, pulverize, merge with Flos Lonicerae medicinal residues, boiling secondary, concentration adds ethanol and stirs evenly, and stands overnight, filters, and reclaims ethanol, after being concentrated into thick paste, adds auxiliary materials and mixing, dries,
3) by 2) gained medicated powder adds 1) the Flos Lonicerae volatile oil inclusion complex of gained；
4) add pharmaceutic adjuvant, after mix homogeneously, obtain powder.
Gained powder can be directly medicinal, it is also possible to it makes various preparation again.
In said method, described inclusion material includes the cyclodextrin derivative such as alpha-cyclodextrin, beta-schardinger dextrin-, gamma-cyclodextrin and 2,6 dimethyl-cyclodextrin.Described excipient substance includes acceptable filler and lubricant, and wherein filler includes starch, modified starch, dextrin, calcium hydrogen phosphate and other acceptable filler adjuvants, and lubricant includes Polyethylene Glycol, calcium stearate, Pulvis Talci and other acceptable lubricants.
Advantages of the present invention and good effect:
This Chinese medicine composition is made according to theory of Chinese medical science and clinical practice experience, has good therapeutic effect for symptoms such as anemopyretic cold and the heating caused, cough and laryngopharynx swelling and pain.Multinomial pharmacodynamic experiment has been carried out with the medicine of the present invention:
One, preclinical pharmacodynamics of San experiment
Showing to have certain antibacterial, antitussive, diaphoresis, antipyretic, antiinflammatory, analgesia, immunoregulation effect, experimental result is as follows:
(1) In Vitro Bacteriostasis
It is shown that the bacterial strains such as staphylococcus aureus (20771), staphylococcus aureus (18153), staphylococcus epidermidis (20289), α-hemolytic streptococcus (181818), streptococcus pneumoniae (B) 31002 are all had bacteriostasis in various degree by the capsule of the present invention.
(2) mice is coughed the impact of reaction
It is shown that the medicine of the present invention can extend mouse cough incubation period to some extent, reduce mouse cough number of times.
(3) impact on normal rat sweat secretion
It is shown that normal rat paw portion sweat secretion is had obvious facilitation.
(4) refrigeration function to rat
It is shown that the exothermic reaction to 2,4-DNP pyrogenicity rat, all there is inhibitory action in various degree.
(5) impact on mice ear
It is shown that Oleum Tiglii induced mice ear swelling is had obvious inhibitory action.
(6) impact on rat thoracic cavity leukocyte
It is shown that rat thoracic cavity leukoplania caused by 1% carrageenin can substantially be suppressed, but pleural effusion be there is no obvious inhibitory action.
(7) analgesic activity to mice
It is shown that acetic acid induced mice writhing response can substantially be suppressed, there is obvious analgesic activity.
(8) impact on mouse immunity
It is shown that hypoimmunity mice carbon powder is cleaned up index K value dramatically increase effect, the potentiation that the immunity of hypoimmunity mice is had by this medicine is described.
But staphylococcus aureus infecting mouse experiments show that, staphylococcus aureus infecting mouse is not had significant protective effect by medicine of the present invention.
Specific experiment data detailed in Example.
Two, clinical pharrnacokinetics experiment
It is shown that this traditional Chinese medicine composition for treating anemopyretic cold is rapid-action, curative effect is high, safe and reliable, has good clinical efficacy, and anemopyretic cold total effective rate reaches 95.3% (detailed in Example).
Detailed description of the invention:
Below in conjunction with embodiment, the present invention being described in further detail, listed embodiment is only that the explanation present invention is not limited to the present invention.
Embodiment 1 is prevented and treats the Chinese medicine powder of anemopyretic cold
Raw material: Radix Helicteris 3.5kg, Radix Picriae felterrae 3.0kg, Flos Lonicerae 3.0kg, Radix Isatidis 3.0kg, Radix Platycodonis 1.0kg, Radix Glycyrrhizae 1.0kg
Preparation method:
1) Flos Lonicerae volatile oil inclusion complex is prepared
A collects volatile oil
Adopting volatile oil catcher to carry out the collection of volatile oil, extracting honeysuckle 2.4kg, add water 4-10 times amount, each 3-5h, extracts 1 time, collects and obtains volatile oil 2ml, yield 0.083%.
B prepares beta-cyclo dextrin included compound
Volatile oil and beta-schardinger dextrin-are mixed and made into inclusion complex in 0.8-1.2:8 (ml/g) ratio: the 100ml that added water by beta-schardinger dextrin-8g makes dissolving, measure volatile oil 0.8-1.2ml and the dilution of a small amount of dehydrated alcohol, slowly it is added drop-wise under being stirred continuously in beta-schardinger dextrin-solution, after continuing stirring in 45～50 DEG C of constant temperature 3 hours, place 24 hours in 5～10 DEG C, filter, in 40 DEG C of cold drying, pulverize, sieve, obtain inclusion complex.
The inclusion complex prepared as stated above is respectively according to two annex XD of China's coastal port, and determination of volatile oil method measures volatile oil content and inclusion complex recovery rate in inclusion complex and calculates average inclusion 92.3%, and average recovery rate is 91.1%.After extracting volatile oil, the remaining Flos Lonicerae medicinal residues of institute give over to lower step and use.
2) being cut off respectively by other medical material, pulverize, merge with Flos Lonicerae medicinal residues, boiling secondary, first time amount of water is 5～12 times of medical material amount, soaks 0.5～1h, heated and boiled 1～3h；Second time amount of water is 5～12 times of medical material amount, boils 1～3h；Filter, merging filtrate, be concentrated into the clear paste that density is 1.10～1.20g/ml, add ethanol, when ethanol content reaches 50～90% (percent by volume) to total amount, stir evenly, stand overnight, filtering, heating under reduced pressure reclaims ethanol, is concentrated into thick paste, add starch 0～1.5kg, mixing, dries, pulverizes and sieves 80～100 orders；
3) by 2) gained medicated powder adds 1) the Flos Lonicerae volatile oil inclusion complex of gained；
4) add modified starch 0～1.5kg, after mix homogeneously, obtain powder.
The Chinese medicine powder of embodiment 2～4 prevention and treatment anemopyretic cold
Preparation method is with embodiment 1, and only material composition is different with consumption.
Embodiment 5 is prevented and treats the Chinese medicine capsules of anemopyretic cold
Ingredient and consumption are with embodiment 1, in preparation method, 1), 2), 3) step is with embodiment 1；
Step 4) add starch and each 0～1.5kg of Pulvis Talci, encapsulated and get final product, every capsules 5g after mix homogeneously.
The Chinese medicine capsules of embodiment 6～8 prevention and treatment anemopyretic cold
Preparation method is with embodiment 5, and only material composition is different with consumption.
Embodiment 9 is prevented and treats the Chinese medicinal tablet of anemopyretic cold
Ingredient and consumption are with embodiment 1, in preparation method, 1), 2), 3) step is with embodiment 1；
Step 4): adding starch 0～1.5kg, granulate after mix homogeneously, dry, tablet machine film-making, every weight is 0.5g.
The Chinese medicinal tablet of embodiment 10～11 prevention and treatment anemopyretic cold
Preparation method is with embodiment 9, and only material composition is different with consumption.
The amount ratio of each embodiment Raw is in Table 1
The amount ratio of each embodiment Raw of table 1.
Preclinical pharmacodynamics of San is tested
(1) In Vitro Bacteriostasis
Adopt plate doubling dilution, the Experimental agents (capsule of embodiment 5-8) diluted is separately added in the sterilising medium being cooled to about 55 DEG C, mixing, make the Drug plates of variable concentrations.Experimental bacteria suspension (the bacterial concentrations 10 such as depletion Staphylococcus aureus, α-hemolytic streptococcus, streptococcus pneumoniae5CFU/ml), draw respectively and plant in the pastille flat board of variable concentrations, cultivate 18h, observed and recorded minimal inhibitory concentration (MIC) for 37 DEG C.
Result is in Table 2.
Table 2 In Vitro Bacteriostasis
It is shown that tried bacterial strain is all had bacteriostasis in various degree by the capsule of the present invention.
Hereinafter in experiment, Experimental agents used is embodiment 6 capsule.
(2) mice ammonia mist is caused the impact coughing reaction
Mice 50, female, male half and half, body weight 20 ± 2g, it is randomly divided into 5 groups, often group 10.Wherein organize ig respectively and give 6.0,3.0, the 1.5/kg of capsule of the present invention for 3；1 group ig gives intensified loquet capsule 3.0/kg；Yu 1 group be blank group, to equivalent distilled water.Every day is administered once, continuous 3d, 1h after last medicine, every Mus constant-pressure atomization ammonia 15s, observes the incubation period of mouse cough, and records mouse cough number of times in 2min.Result is in Table 3.
Mice ammonia mist is caused the impact coughing reaction by the capsule of table 3. present invention
T checks, and compares * P < 0.05**P < 0.01***P < 0.001 with matched group
It is shown that 6.0,3.0, the 1.5/kg of capsule of the present invention all has prolongation mouse cough incubation period to some extent, reduce mouse cough number of times.
(3) impact (colouring) on normal rat paw sweat secretion
Take rat 50, male and female half and half, body weight 160 ± 40g, be randomly divided into 5 groups, often group 10.Wherein organize ig respectively and give 6.0,3.0, the 1.5/kg of capsule of the present invention for 3；1 group ig gives Ephedrae Decoction 1g/kg；Yu 1 group be blank, ig is to equal-volume distilled water.After administration, rat is respectively implanted in rat fixator, face upward position to fix, expose double; two hind leg, dip dehydrated alcohol gently by foot sole of the foot portion dirt scrub with cotton swab, then wipe dry gently with dry cotton swab, 15min coats and field-Gao Yuan Shi reagent A liquid in rat paw portion skin upon administration, treating fully dried, after administration, 30min is very thin coats B liquid, observes after 30min and records antiperspirant and counts, one antiperspirant presses the difference of 1 integral and calculating, comparative control group and medicine group.Result is in Table 4.
The impact on normal rat paw sweat secretion of the capsule of table 4. present invention
T checks, and compares * * P < 0.01 with matched group
It is shown that normal rat paw portion sweat secretion is all had obvious facilitation by 6.0,3.0, the 1.5/kg of capsule of the present invention.
(4) refrigeration function to 2,4-DNP pyrogenicity rat
Rat body weight 250 ± 40g, female, male half and half, before experiment, water 16h is can't help in fasting, and the same day was measured rat temperature 2 times in experiment, chooses the Temperature changing rat less than 0.3 DEG C 50, is divided into 4 groups, often group 10.Wherein organize ig respectively and give 6.0,3.0, the 1.5/kg of capsule of the present invention for 3；1 group of ig is to aspirin 0.3g/kg；Yu 1 group be blank, ig is to equivalent distilled water.After medicine, 30min is in each Mus dorsal sc accurate injection 2,2, 4-dinitrophenol solution 20mg/kg, after pyrogenicity, 45min respectively organizes and is administered once, after pyrogenicity respectively at 0.5,1,2,3,4,5h measure rat temperature 1 time, survey 6 times altogether, calculate each group of rat temperature changing value.Result is in Table 5.
The table 5. capsule of the present invention refrigeration function to 2,4-DNP pyrogenicity rat
T checks, and compares * P < 0.05**P < 0.01***P < 0.001 with matched group
It is shown that the exothermic reaction that 6.0,3.0, the 1.5/kg of capsule of the present invention is to 2,4-DNP pyrogenicity rat, all there is inhibitory action in various degree.
(5) impact on Oleum Tiglii induced mice ear swelling
Mice 50, female, male half and half, body weight 20 ± 2g, it is randomly divided into 5 groups, often group 10.Wherein organize ig respectively and give 6.0,3.0, the 1.5/kg of capsule of the present invention for 3；1 group ig gives dexamethasone tablet 2.5/kg；Yu 1 group be blank, ig is to equivalent distilled water.30min after medicine, the left ear of each Mus causes inflammation with 2% Oleum Tiglii mixture 0.05ml/ ear, and auris dextra compares.After causing inflammation, 30min is administered once again, mice breaks after 4h cervical vertebra and puts to death, cut two ears, garden auricle is laid at coating position respectively with diameter 9mm card punch, weigh mice left and right ear weight with analytical balance, using its difference as inflammatory swelling degree, and calculate swelling inhibition percentage.Result is in Table 6.
The impact on Oleum Tiglii induced mice auricular concha swelling of the capsule of table 6. present invention
T checks, and compares * * * P < 0.001*P < 0.05 with matched group
It is shown that Oleum Tiglii induced mice ear swelling is had obvious inhibitory action by the 6.0/kg of capsule of the present invention.
(6) impact on rat thoracic cavity leukoplania
Take rat 50, male and female half and half, body weight 210～240g, be divided into 5 groups by body weight, often group 10.Wherein 3 groups of ig give 6.0,3.0, the 1.5/kg of capsule of the present invention；1 group is positive controls, and ig gives dexamethasone tablet 2.5/kg, remaining 1 group be blank group, ig give wait capacity distilled water.It is administered every day 1 time, continuous 10d, 1h after last administration, under ether light anaesthesia, only causes inflammation from right side intrapleural injection 1% carrageenin 0.2ml/, put to death rat after 5h, open thoracic cavity, with suction pipe sucking-off pleural effusion, record transudate volume counted for total White.Result is in Table 7.
The impact on rat thoracic cavity leukoplania of the capsule of table 7. present invention
T checks, and compares * P < 0.05**P < 0.01 with matched group
It is shown that 6.0,3.0, the 1.5/kg of capsule of the present invention all can substantially suppress rat thoracic cavity leukoplania caused by 1% carrageenin, but pleural effusion be there is no obvious inhibitory action.
(7) impact of Dichlorodiphenyl Acetate induced mice writhing response
Mice 50, female, male half and half, body weight 20 ± 2g, it is randomly divided into 5 groups, often group 10.Wherein organize ig respectively and give 6.0,3.0, the 1.5/kg of capsule of the present invention for 3；1 group ig gives aspirin 0.3g/kg；Yu 1 group be blank, ig is to equivalent distilled water.30min after administration, each Mus lumbar injection 0.6% glacial acetic acid 0.2ml/ respectively only, observes the writhing response number of times occurred in 20min after injecting.Result is in Table 8.
The impact of the capsule Dichlorodiphenyl Acetate induced mice writhing response of table 8. present invention
T checks, and compares * P < 0.05**P < 0.01***P < 0.001 with matched group
It is shown that 6.0,3.0, the 1.5/kg of capsule of the present invention all can substantially suppress acetic acid induced mice writhing response, there is obvious analgesic activity.
(8) on the impact of Carbon clearance function in hypoimmunity mice body
Take mice 60, male and female half and half, body weight 18～22g, be uniformly divided into 6 groups by body weight, often group 10.Wherein 3 groups of ig give 6.0,3.0, the 1.5/kg of capsule of the present invention；2 groups is blank group and model group, and ig gives to wait capacity distilled water；Yu 1 group be positive controls, ig gives SHENQI PIAN 0.75g/kg.It is administered every day 1 time, successive administration 7d.In 6dig administration simultaneously, except blank group, all the other 5 groups of mices subcutaneous injection prednisolone acetate 25mg/kg respectively make immunodeficiency models, after 24h (after not secondary administration 1h), the india ink 0.1ml/10g body weight of mouse tail vein injection 10%, after injection, 2min and 7min orbital venous plexus is taken a blood sample 20 μ l, it is dissolved in 2ml0.1%Na2CO3 solution, put 722 type spectrophotometers and measure trap in 680nm place, and take liver, spleen weighs its organ coefficient of calculating, calculate carbon powder and clean up index K and index α is cleaned up in correction.Result is in Table 9.
The impact on mice Carbon clearance ability of the capsule of table 9. present invention
T checks, and compares with matched groupΔΔP<0.01ΔΔΔP < 0.001；Compare with prednisolone acetate (model group), * P < 0.05
It is shown that hypoimmunity mice carbon powder is cleaned up index K value by 6.0,3.0, the 1.5/kg of capsule of the present invention dramatically increases effect, the potentiation that the immunity of hypoimmunity mice is had by this medicine is described.
(9) protective effect that mouse experiment antibacterial is infected
Mice 80, female, male half and half, body weight 20 ± 2g, it is randomly divided into 4 groups, often group 20.Wherein organize oral cavity respectively and give 21.6, the 5.4/kg of capsule of the present invention for 2；1 group ig gives acetyl Luo Xuan mycin 1g/kg；Yu 1 group be blank, ig is to equal-volume distilled water.Every day is administered once, continuous 3d.Staphylococcus aureus is inoculated in 2ml nutrient broth, cultivate 8h for 37 DEG C, take 0.1ml transferred species in 10ml nutrient broth, cultivate 18h for 37 DEG C, for experiment original bacteria liquid, original bacteria liquid physiological saline solution is suitably diluted, is finally diluted to infection animal 100% minimum lethal dose (MLD) with 5% high activity dried yeast liquid.1h after last medicine, the bacteria suspension 0.5ml of the MLD (1 × 105CFU/ml) determined in every mouse peritoneal injection prerun, after microbiological contamination, 2h is administered 1 time again, Continuous Observation 7d, records each group of dead mouse situation.Result is in Table 10.
The capsule of table 10. present invention vivo bacteria corrosion action to staphylococcus aureus infecting mouse
X2Inspection, compares with matched group, * * P < 0.01
It is shown that staphylococcus aureus infecting mouse is not had significant protective effect by 21.6, the 5.4/kg of capsule of the present invention.
Clinical pharrnacokinetics is tested
(1) case selection standard:
Disease is shown in heating micro evil wind, and antiperspirant is let out not smooth, distending pain in the head, cough, and expectorant is viscous or yellow, parched throat, laryngopharynx swelling and pain, and nasal obstruction flows turbid nasal discharge, thirst with desire to drink, tongue tip side of red, thin lingual fur or micro-Huang, floating and rapid pulse person.
(2) Therapeutic Method:
Embodiment 1 medicated powder for oral administration, 3 times on the one, 7th be a course for the treatment of, optionally adds treatment after the course for the treatment of.The medicine without other treatment primary disease is required during observation.
(3) effect criterion:
1, effective: anemopyretic cold related symptoms disappears, and sign and lab testing are without exception.
2, take a turn for the better: anemopyretic cold related symptoms, sign and lab testing have improvement.
3, invalid: anemopyretic cold related symptoms, sign and lab testing are all without improving.
(4) result:
Total case load 85 people is treated in my Out-patient Department portion altogether, wherein: effective 75 people, 6 people that take a turn for the better, invalid 4 people, total effective rate 95.3%.Result above has pointed out this Chinese medicine composition that anemopyretic cold has good clinical efficacy.
(5) model case:
Case 1
Revive certain, man, 7 years old.In February, 2002, main suit caused heating 4d because of upper sense, and with quiet of penicillin, after transfusion, body temperature can be down to normally every time, after crossing 2～3h, body temperature starts again to raise, with afternoon, night for very, and body temperature 38.5 DEG C～40.0 DEG C, nasal obstruction, watery nasal discharge, cough, pharyngalgia, red tongue, yellow fur, floating and tense pulse.Lab testing: leukocyte 11.0 × l09/ L, neutrophilic granulocyte 0.72%.Chest X-rays: double; two lung marking strengthen.Give the Drug therapy in the present embodiment 1, generate heat after medication 2d and namely stop, fully recover after 5d.
Song, man, 27 years old, in June, 2002 main suit recurrent cough 5d, generate heat 2d, once Oral Acetyl Spiramycin sheet 2d treatment, symptom is without improvement.Body temperature 39.6 DEG C, pharyngeal congestion, antiadoncus, leukocyte 13.0 × 109/ L, neutrophilic granulocyte 0.82%.Give the Drug therapy in the present embodiment 1, generate heat after medication 1d and namely stop, fully recover after 7d.
Huang, female, 25 years old, patient's heating, cough companion malaise 3d went to a doctor on August 30th, 2003.There is heating, cough in main suit's 3d cause after suffering from cold, have a little mucoid expectorant, headache, and pharyngalgia is uncomfortable, and general fatigue is unable, loss of appetite, feels sick.(medicines such as KUAIKE, cefradine, SHUANGHUANLIAN, ampicillin are used) after private clinic is treated.The state of an illness still increases the weight of gradually.Have a medical check-up: body temperature 38.5 DEG C.110 beats/min of pulse.Breathe 21 beats/min.Sanity, listlessness.Swallow red.Two pulmonary respiration sounds are low, audible and dry moist rale.Leukocyte 15.0 × 109/ L, neutrophilic granulocyte 0.86%.Rabat shows bottom right pulmonary infection.Give the Drug therapy in the present embodiment 1, generate heat after medication 3d and namely stop, fully recover after 12d.
Claims (4)
1. the compound recipe consisted of the following composition application in the medicine of preparation prevention and treatment anemopyretic cold:
Radix Helicteris 6～8 parts, Radix Picriae felterrae 5～7 parts, Radix Isatidis 5～7 parts, the volatile oil made with 5～7 portions of Flos Loniceraes, Radix Platycodonis 1.6～2.4 parts, 1.6～2.4 parts of Radix Glycyrrhizae；Described part is weight portion.
2. application according to claim 1, the weight ratio of the raw material preparing described medicine is: Radix Helicteris 7 parts, Radix Picriae felterrae 7 parts, Flos Lonicerae 6 parts, Radix Isatidis 6 parts, Radix Platycodonis 2 parts and 2 parts of Radix Glycyrrhizae.
3. a medicine for prevention and treatment anemopyretic cold, is made up of following component:
Radix Helicteris 6～8 parts, Radix Picriae felterrae 5～7 parts, Radix Isatidis 5～7 parts, the volatile oil made with 5～7 portions of Flos Loniceraes, Radix Platycodonis 1.6～2.4 parts, 1.6～2.4 parts of Radix Glycyrrhizae；Described part is weight portion.
4. medicine according to claim 3, its dosage form is oral agents, selected from powder, capsule, tablet or electuary.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410082674.0A CN103816281B (en) | 2013-12-24 | 2014-03-07 | A kind of Chinese medicine composition of prevention and treatment anemopyretic cold |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310731421.7 | 2013-12-24 | ||
| CN201310731421 | 2013-12-24 | ||
| CN2013107314217 | 2013-12-24 | ||
| CN201410082674.0A CN103816281B (en) | 2013-12-24 | 2014-03-07 | A kind of Chinese medicine composition of prevention and treatment anemopyretic cold |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103816281A CN103816281A (en) | 2014-05-28 |
| CN103816281B true CN103816281B (en) | 2016-06-29 |
Family
ID=50751762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410082674.0A Active CN103816281B (en) | 2013-12-24 | 2014-03-07 | A kind of Chinese medicine composition of prevention and treatment anemopyretic cold |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103816281B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105560554A (en) * | 2016-02-23 | 2016-05-11 | 广西梧州制药（集团）股份有限公司 | Traditional Chinese medicine composition for diminishing inflammation and relieving sore throat and preparation method thereof |
| CN106038690A (en) * | 2016-06-01 | 2016-10-26 | 湖南安邦制药有限公司 | Preparing method of ligusticum wallichii tea conditioning granules |
| CN107050087A (en) * | 2017-03-24 | 2017-08-18 | 华润三九（郴州）制药有限公司 | It is a kind of to treat medicine of anemopyretic cold and its preparation method and application |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100478004C (en) * | 2005-12-23 | 2009-04-15 | 桂林三金药业股份有限公司 | Chinese medicinal composistion for treating common cold, its preparation method and quality control method |
| CN101023764A (en) * | 2006-02-20 | 2007-08-29 | 耿军 | Chrysanthemum epidermic-prevention pharynt-clearing tea and preparing method |
| CN101181393A (en) * | 2007-11-22 | 2008-05-21 | 张树球 | Chinese medicine preparation for curing common cold and producing method thereof |
| CN101690745B (en) * | 2009-10-30 | 2011-08-31 | 福州市仓山区金点子信息咨询有限公司 | Chinese medicinal composition for preventing and treating flu |
| CN102114197A (en) * | 2010-05-13 | 2011-07-06 | 于进香 | Traditional Chinese medicine oral decoction for treating influenza |
| CN102397338A (en) * | 2010-09-16 | 2012-04-04 | 上海玉森新药开发有限公司 | Chinese medicine composition for treating influenza |
| CN103341086A (en) * | 2013-07-16 | 2013-10-09 | 冯宇伟 | Medicine for preventing and treating influenza and preparation method thereof |
-
2014
- 2014-03-07 CN CN201410082674.0A patent/CN103816281B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103816281A (en) | 2014-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101167811A (en) | External-applied preparation with anti-inflammation, itching-relieving and sterilization function and manufacturing method and application thereof | |
| CN103768308B (en) | A kind of pharmaceutical composition that is used for the treatment of the infection of the upper respiratory tract and preparation method thereof | |
| CN101953985A (en) | Drug with function of removing heat from lung to relieve cough | |
| CN105560372A (en) | Traditional Chinese medicine spray for treating rhinitis and preparation method thereof | |
| CN102319294B (en) | Double-vanilla preparation and preparation method thereof | |
| CN103977314A (en) | Medicinal composition for treating respiratory diseases as well as preparation method and application of medicinal composition | |
| CN104127749A (en) | Traditional Chinese medicament for treating organic phosphorus pesticide poisoning and preparation method thereof | |
| CN114073730A (en) | Traditional Chinese medicine composition for preventing or treating air-conditioning syndrome | |
| CN103816281B (en) | A kind of Chinese medicine composition of prevention and treatment anemopyretic cold | |
| CN104013846A (en) | Traditional Chinese medicine composition for treating dental ulcer and application thereof | |
| CN101618146A (en) | Complex traditional Chinese medicine preparation for treating upper respiratory tract infection and preparation method thereof | |
| CN103961614B (en) | Chinese medicine composition for treating respiratory disease and its production and use | |
| CN104983968B (en) | Antipyretic traditional Chinese medicine composition and preparation method thereof | |
| CN101322749B (en) | Chinese medicine oral liquid for treating wind-heat cold and preparation thereof | |
| CN102139051A (en) | Application of soft capsule capable of clearing heat and eliminating toxin in preparation of medicament for treating viral pneumonia | |
| CN104474021A (en) | Traditional Chinese medicine composition for treatment of exterior heat and preparation method thereof | |
| CN100563677C (en) | A kind of moistening and cleaning throat Chinese medicine preparation | |
| CN1966051B (en) | Antivirus medicament for resisting virus | |
| CN103977226A (en) | Traditional Chinese medicine compound preparation for treating pediatric cold and preparation method thereof | |
| CN103860695B (en) | A kind of Chinese medicine composition and preparation method for the treatment of pyretic stranguria syndrome of dampness-heat in lower jiao | |
| CN103961654B (en) | A kind of White staphylococcus sheet and preparation method thereof | |
| CN101810675A (en) | Medicament for treating pharyngitis | |
| CN103251845A (en) | Composition for clearing heat from throat and wetting throat | |
| CN107095977A (en) | A kind of medicament and its pharmaceutical formulation and preparation method with the malicious effect of fire row of dispelling | |
| CN103566029B (en) | Pharmaceutical composition for treating respiratory diseases and preparation method and usage thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Song Zhizhao Inventor after: Zhang Ying Inventor after: Liang Wei Inventor after: Ma Zhonglin Inventor after: Liu Yuan Inventor after: Wen Zhiyun Inventor after: Li Xingyu Inventor after: Lantaijin Inventor before: Lantaijin Inventor before: Liu Yuan Inventor before: Zhang Ying Inventor before: Song Zhizhao Inventor before: Wen Zhiyun Inventor before: Li Xingyu |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LAN TAIJIN LIU YUAN ZHANG YING SONG ZHIZHAO WEN ZHIYUN LI XINGYU TO: SONG ZHIZHAO ZHANG YING LIANG WEI MA ZHONGLIN LIU YUAN WEN ZHIYUN LI XINGYU LAN TAIJIN |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20140528 Assignee: GUANGXI WUZHOU SANHE PHARMACEUTICAL CO.,LTD. Assignor: GUANGXI INSTITUTE OF CHINESE MEDICINE & PHARMACEUTICAL SCIENCE Contract record no.: X2023980044815 Denomination of invention: A Traditional Chinese Medicine Composition for Preventing and Treating Wind Heat and Cold Granted publication date: 20160629 License type: Common License Record date: 20231031 |
|
| EE01 | Entry into force of recordation of patent licensing contract |